Movement for Change
Patients and doctors advocate for testing lower effective doses of cancer drugs to reduce unnecessary suffering.
Rethinking Drug Development
Cancer Drug Evolution: Shift from “maximum tolerated dose” to finding the lowest effective dose.
Impact on Patients
Patient Stories: Jill Feldman and Lesley Kailani Glenn share their experiences and challenges with current drug dosing.
Regulatory Action
FDA’s Initiative: Project Optimus urges drugmakers to prioritize tolerability and efficacy in early trials.
Future of Cancer Drug Development
Drugs of Tomorrow: Emphasis on individualized dosing and quality of life for patients.